首页 > 最新文献

Drug metabolism and personalized therapy最新文献

英文 中文
Application of herbal liniment ('Ṭilā) in the management of pain and disability of chronic migraine: a randomized controlled trial. 应用草药搽剂(Ṭilā)治疗慢性偏头痛的疼痛和残疾:一项随机对照试验。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2026-02-02 DOI: 10.1515/dmpt-2025-0079
Suresh Kumar Saral, Abdul Nasir Ansari, Mohd Nayab, Khalid Rahim Wani

Objectives: Chronic migraine is a prevalent and disabling neurological disorder affecting 1-3 % of the global population. Ancient Unani physicians have described herbal liniment ('Ṭilā) as a treatment modality for chronic migraine. This study aimed to evaluate its efficacy in managing the condition.

Methods: A randomized controlled trial was conducted on 36 patients with chronic migraine. Participants were divided into two groups: the test group (n=24), which received herbal liniment applied locally once daily for 15 days, and the control group (n=12), which underwent transcutaneous electrical nerve stimulation (TENS) for 30 min daily, 5 days a week, over 2 weeks. Outcomes were measured using the Visual Analogue Scale (VAS), headache frequency, and the Migraine Disability Assessment Scale (MIDAS) on days 15, 30, 60, and 90.

Results: Both groups showed significant improvement within the groups in headache frequency (p<0.0001). The test group demonstrated greater effectiveness, with larger reductions in headache frequency (mean difference 39.63; p<0.0001), VAS (mean difference 3.96; p<0.001), and MIDAS (mean difference 2.25; p=0.003).

Conclusions: Herbal liniment effectively reduced migraine frequency, intensity, and disability. Larger studies are needed to validate these findings and assess long-term outcomes.

目的:慢性偏头痛是一种普遍和致残的神经系统疾病,影响全球人口的1- 3% %。古代乌纳尼医生将草药搽剂(Ṭilā)描述为慢性偏头痛的一种治疗方式。本研究旨在评估其对病情的治疗效果。方法:对36例慢性偏头痛患者进行随机对照试验。参与者被分为两组:试验组(n=24)接受草药搽剂局部涂抹,每天一次,持续15天;对照组(n=12)接受经皮神经电刺激(TENS),每天30次 min,每周5天,持续2周。在第15、30、60和90天使用视觉模拟量表(VAS)、头痛频率和偏头痛残疾评估量表(MIDAS)测量结果。结果:两组患者头痛频率均有显著改善(结论:草药搽剂有效降低偏头痛频率、强度和致残性。需要更大规模的研究来验证这些发现并评估长期结果。
{"title":"Application of herbal liniment (<i>'Ṭilā</i>) in the management of pain and disability of chronic migraine: a randomized controlled trial.","authors":"Suresh Kumar Saral, Abdul Nasir Ansari, Mohd Nayab, Khalid Rahim Wani","doi":"10.1515/dmpt-2025-0079","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0079","url":null,"abstract":"<p><strong>Objectives: </strong>Chronic migraine is a prevalent and disabling neurological disorder affecting 1-3 % of the global population. Ancient Unani physicians have described herbal liniment (<i>'Ṭilā</i>) as a treatment modality for chronic migraine. This study aimed to evaluate its efficacy in managing the condition.</p><p><strong>Methods: </strong>A randomized controlled trial was conducted on 36 patients with chronic migraine. Participants were divided into two groups: the test group (n=24), which received herbal liniment applied locally once daily for 15 days, and the control group (n=12), which underwent transcutaneous electrical nerve stimulation (TENS) for 30 min daily, 5 days a week, over 2 weeks. Outcomes were measured using the Visual Analogue Scale (VAS), headache frequency, and the Migraine Disability Assessment Scale (MIDAS) on days 15, 30, 60, and 90.</p><p><strong>Results: </strong>Both groups showed significant improvement within the groups in headache frequency (p<0.0001). The test group demonstrated greater effectiveness, with larger reductions in headache frequency (mean difference 39.63; p<0.0001), VAS (mean difference 3.96; p<0.001), and MIDAS (mean difference 2.25; p=0.003).</p><p><strong>Conclusions: </strong>Herbal liniment effectively reduced migraine frequency, intensity, and disability. Larger studies are needed to validate these findings and assess long-term outcomes.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From warfarin resistance to warfarin overdose: an unusual case report. 从华法林耐药到华法林过量:一个不寻常的病例报告。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2026-01-26 DOI: 10.1515/dmpt-2025-0062
Mehmet Uğur Çalışkan

Objectives: Warfarin resistance represents a rare yet clinically significant challenge, especially among patients with mechanical heart valves. It may result from either hereditary or acquired factors.

Case presentation: A 27-year-old male patient with a history of aortic and mitral valve replacement was followed with subtherapeutic International Normalized Ratio (INR) of 1.8-2.0 despite receiving 20 mg/day of warfarin. He was hospitalized for evaluation, and potential acquired causes of warfarin resistance were excluded. The patient was discharged with a plan for close INR monitoring. Following the initiation of lorazepam and olanzapine for a comorbid psychiatric condition, he re-presented with bleeding manifestations due to warfarin overdose. Notably, his apparent warfarin resistance resolved after the addition of these medications, and he has since been maintained within the therapeutic INR range on a stable warfarin dose of 5 mg/day.

Conclusions: Warfarin is known to interact with numerous medications, and new drug interactions continue to be reported in the literature. Although no major interactions with lorazepam or olanzapine have been previously documented, in this case the concomitant initiation of these agents appeared to overcome warfarin resistance. This clinical course was remarkable for the apparent resolution of warfarin resistance, raising the possibility of underlying pharmacologic interactions.

目的:华法林耐药是一种罕见但临床意义重大的挑战,特别是在机械心脏瓣膜患者中。它可能由遗传或后天因素引起。病例介绍:一名27岁男性患者,有主动脉瓣和二尖瓣置换术史,尽管接受20 mg/天的华法林治疗,但亚治疗期国际标准化比率(INR)为1.8-2.0。他住院接受评估,排除了潜在的获得性华法林耐药原因。患者出院时计划密切监测INR。在开始使用劳拉西泮和奥氮平治疗共病精神疾病后,他再次出现因华法林过量而出血的表现。值得注意的是,在添加这些药物后,他明显的华法林耐药性消失了,并且在华法林5 mg/天的稳定剂量下,他一直保持在治疗INR范围内。结论:华法林已知与许多药物相互作用,并且文献中不断报道新的药物相互作用。虽然之前没有文献记载与劳拉西泮或奥氮平的主要相互作用,但在本病例中,同时开始使用这些药物似乎克服了华法林耐药性。这个临床过程对于华法林耐药性的明显解决是显着的,增加了潜在的药物相互作用的可能性。
{"title":"From warfarin resistance to warfarin overdose: an unusual case report.","authors":"Mehmet Uğur Çalışkan","doi":"10.1515/dmpt-2025-0062","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0062","url":null,"abstract":"<p><strong>Objectives: </strong>Warfarin resistance represents a rare yet clinically significant challenge, especially among patients with mechanical heart valves. It may result from either hereditary or acquired factors.</p><p><strong>Case presentation: </strong>A 27-year-old male patient with a history of aortic and mitral valve replacement was followed with subtherapeutic International Normalized Ratio (INR) of 1.8-2.0 despite receiving 20 mg/day of warfarin. He was hospitalized for evaluation, and potential acquired causes of warfarin resistance were excluded. The patient was discharged with a plan for close INR monitoring. Following the initiation of lorazepam and olanzapine for a comorbid psychiatric condition, he re-presented with bleeding manifestations due to warfarin overdose. Notably, his apparent warfarin resistance resolved after the addition of these medications, and he has since been maintained within the therapeutic INR range on a stable warfarin dose of 5 mg/day.</p><p><strong>Conclusions: </strong>Warfarin is known to interact with numerous medications, and new drug interactions continue to be reported in the literature. Although no major interactions with lorazepam or olanzapine have been previously documented, in this case the concomitant initiation of these agents appeared to overcome warfarin resistance. This clinical course was remarkable for the apparent resolution of warfarin resistance, raising the possibility of underlying pharmacologic interactions.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Whole genome circRNA profiling of Withania somnifera in human neuroblastoma SK-N-SH cells. 人神经母细胞瘤SK-N-SH细胞中somnifera的全基因组circRNA分析。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-17 DOI: 10.1515/dmpt-2025-0064
Anand Bhaskar, Dilip Mehta, Bhirisha Sharma, Jash Trivedi, Dhananya S, Manju Moorthy, Gopalakrishna Ramaswamy, Sujit Nair

Objectives: Defined by their unique covalently closed loop, circular RNAs (circRNAs) are a specific class of noncoding RNAs known for their stability and resilience against degradation. They act as microRNA sponges, transcriptional regulators, and modulators of protein interactions. Withania somnifera (WS), a prominent member of the Solanaceae family, is renowned for its anti-oxidative and neuroprotective properties. Although circRNAs are recognized as critical regulators in neurological disorders, their putative roles in eliciting the health-beneficial effects of WS, also known as Ashwagandha, are still unexplored.

Methods: This study investigates WS-modulated global circRNA expression profiles in the SK-N-SH human neuroblastoma cell line, a widely used model for brain-related diseases. We conducted whole genome circRNA profiling using sequencing to identify differentially expressed circRNAs upon WS treatment.

Results: A total of 26,489 circRNAs were detected, out of which 1,515 were novel. Dose-dependent and temporal differential gene expression analysis found 26 upregulated and 20 downregulated circRNAs which were linked to pathways relevant to neuroinflammation, synaptic plasticity and neuronal survival through functional and pathway enrichment analysis.

Conclusions: This study sheds light on the regulatory roles of circRNAs in WS's therapeutic effects, suggesting that modulating circRNA expression may be a key mechanism by which it exerts its benefits. These findings open new avenues for WS-based therapeutic strategies for brain-related diseases, thereby highlighting the therapeutic utility of circRNAs in neurological contexts.

目的:环状rna (circRNAs)是一类特殊的非编码rna,以其独特的共价闭环而闻名,其稳定性和抗降解的弹性。它们充当microRNA海绵、转录调节因子和蛋白质相互作用的调节因子。Withania somnifera (WS)是茄科植物中的一员,以其抗氧化和神经保护作用而闻名。尽管circrna被认为是神经系统疾病的关键调节因子,但它们在引发WS(也称为Ashwagandha)的有益健康效应方面的假定作用仍未得到探索。方法:本研究在SK-N-SH人神经母细胞瘤细胞系中研究ws调控的全球circRNA表达谱,SK-N-SH是一种广泛使用的脑相关疾病模型。我们使用测序技术进行了全基因组circRNA分析,以鉴定WS治疗时差异表达的circRNA。结果:共检测到26,489个环状rna,其中1,515个是新发现的。剂量依赖性和时间差异基因表达分析通过功能和通路富集分析发现26个上调和20个下调的circrna与神经炎症、突触可塑性和神经元存活相关的通路有关。结论:本研究揭示了circRNA在WS治疗作用中的调节作用,提示调节circRNA表达可能是其发挥作用的关键机制。这些发现为基于ws的脑相关疾病治疗策略开辟了新的途径,从而突出了circRNAs在神经学背景下的治疗效用。
{"title":"Whole genome circRNA profiling of <i>Withania somnifera</i> in human neuroblastoma SK-N-SH cells.","authors":"Anand Bhaskar, Dilip Mehta, Bhirisha Sharma, Jash Trivedi, Dhananya S, Manju Moorthy, Gopalakrishna Ramaswamy, Sujit Nair","doi":"10.1515/dmpt-2025-0064","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0064","url":null,"abstract":"<p><strong>Objectives: </strong>Defined by their unique covalently closed loop, circular RNAs (circRNAs) are a specific class of noncoding RNAs known for their stability and resilience against degradation. They act as microRNA sponges, transcriptional regulators, and modulators of protein interactions. <i>Withania somnifera</i> (WS), a prominent member of the Solanaceae family, is renowned for its anti-oxidative and neuroprotective properties. Although circRNAs are recognized as critical regulators in neurological disorders, their putative roles in eliciting the health-beneficial effects of WS, also known as Ashwagandha, are still unexplored.</p><p><strong>Methods: </strong>This study investigates WS-modulated global circRNA expression profiles in the SK-N-SH human neuroblastoma cell line, a widely used model for brain-related diseases. We conducted whole genome circRNA profiling using sequencing to identify differentially expressed circRNAs upon WS treatment.</p><p><strong>Results: </strong>A total of 26,489 circRNAs were detected, out of which 1,515 were novel. Dose-dependent and temporal differential gene expression analysis found 26 upregulated and 20 downregulated circRNAs which were linked to pathways relevant to neuroinflammation, synaptic plasticity and neuronal survival through functional and pathway enrichment analysis.</p><p><strong>Conclusions: </strong>This study sheds light on the regulatory roles of circRNAs in WS's therapeutic effects, suggesting that modulating circRNA expression may be a key mechanism by which it exerts its benefits. These findings open new avenues for WS-based therapeutic strategies for brain-related diseases, thereby highlighting the therapeutic utility of circRNAs in neurological contexts.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring two medicinally important Selinum species: bridging traditional knowledge with modern pharmacological insights. 探索两个重要的药用硒物种:桥接传统知识与现代药理学的见解。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-17 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0043
Ruchika Kumari, Palak Thakur, Vipasha Sharma, Ashun Chaudhary

Background: Selinum is an important genus in the Apiaceae family, known for its essential oil-bearing medicinal properties. Selinum vaginatum C. B. Clarke and Ligusticopsis wallichiana (DC.) Pimenov & Kljuykov (Syn. Selinum wallichianum (DC.) Raizada & H. O. Saxena and Selinum tenuifolium Wall. ex DC.) are the two important species found in Himachal Pradesh, India.

Content: The primary objective of this review is to present an updated report on the phytochemistry, traditional knowledge, and pharmacological profile of two species of the genus Selinum that are found in the Western Himalayas.

Summary: The genus Selinum is commonly referred to as Bhutakeshi or Bhootkeshi. Strong evidence supports Selinum's claims for its traditional ethnomedical importance and is used to treat cardiovascular diseases, asthma, toothache, mental disorders and diabetes. It is also used as an insect repellent and in magico-religious practices. The plant has antioxidant, anti-inflammatory, anticancer, anticonvulsant, and antimicrobial activities. The plant is rich in phenols, flavonoids, alkaloids, and terpenoids that contribute to its bioactivities.

Outlook: This review outlines the important phytochemicals, traditional uses, and potential pharmacological properties of Selinum species. Further investigation is needed to elucidate the mechanistic importance of its bioactive components in drug development processes and to investigate the therapeutic potential at the clinical level.

背景:Selinum是蜂科植物中的重要属,因其精油的药用价值而闻名。阴道Selinum c.b. Clarke和Ligusticopsis wallichiana (DC.)皮门诺夫和克列伊科夫(Syn. Selinum wallichianum, DC.)Raizada & H. O. Saxena和Selinum tenufolium壁。)是在印度喜马偕尔邦发现的两个重要物种。内容:这篇综述的主要目的是介绍在西喜马拉雅山脉发现的两种Selinum属植物的植物化学、传统知识和药理学特征的最新报告。摘要:Selinum属通常被称为Bhutakeshi或Bhootkeshi。强有力的证据支持Selinum对其传统民族医学重要性的说法,并用于治疗心血管疾病、哮喘、牙痛、精神障碍和糖尿病。它也被用作驱虫剂和魔法宗教活动。该植物具有抗氧化、抗炎、抗癌、抗惊厥和抗菌活性。这种植物富含酚类、黄酮类、生物碱和萜类,有助于其生物活性。展望:本文综述了硒属植物的重要化学成分、传统用途和潜在药理特性。需要进一步的研究来阐明其生物活性成分在药物开发过程中的机制重要性,并在临床水平上研究其治疗潜力。
{"title":"Exploring two medicinally important <i>Selinum</i> species: bridging traditional knowledge with modern pharmacological insights.","authors":"Ruchika Kumari, Palak Thakur, Vipasha Sharma, Ashun Chaudhary","doi":"10.1515/dmpt-2025-0043","DOIUrl":"10.1515/dmpt-2025-0043","url":null,"abstract":"<p><strong>Background: </strong><i>Selinum</i> is an important genus in the Apiaceae family, known for its essential oil-bearing medicinal properties. <i>Selinum vaginatum</i> C. B. Clarke and <i>Ligusticopsis wallichiana</i> (DC.) Pimenov & Kljuykov (Syn. <i>Selinum wallichianum</i> (DC.) Raizada & H. O. Saxena and <i>Selinum tenuifolium</i> Wall. ex DC.) are the two important species found in Himachal Pradesh, India.</p><p><strong>Content: </strong>The primary objective of this review is to present an updated report on the phytochemistry, traditional knowledge, and pharmacological profile of two species of the genus <i>Selinum</i> that are found in the Western Himalayas.</p><p><strong>Summary: </strong>The genus <i>Selinum</i> is commonly referred to as Bhutakeshi or Bhootkeshi. Strong evidence supports <i>Selinum</i>'s claims for its traditional ethnomedical importance and is used to treat cardiovascular diseases, asthma, toothache, mental disorders and diabetes. It is also used as an insect repellent and in magico-religious practices. The plant has antioxidant, anti-inflammatory, anticancer, anticonvulsant, and antimicrobial activities. The plant is rich in phenols, flavonoids, alkaloids, and terpenoids that contribute to its bioactivities.</p><p><strong>Outlook: </strong>This review outlines the important phytochemicals, traditional uses, and potential pharmacological properties of <i>Selinum</i> species. Further investigation is needed to elucidate the mechanistic importance of its bioactive components in drug development processes and to investigate the therapeutic potential at the clinical level.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"199-215"},"PeriodicalIF":0.0,"publicationDate":"2025-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dr. José María Cantú Garza award. Jose Maria Cantu Garza博士奖。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-12-16 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0086
Ingrid Fricke-Galindo, Adrián LLerena
{"title":"Dr. José María Cantú Garza award.","authors":"Ingrid Fricke-Galindo, Adrián LLerena","doi":"10.1515/dmpt-2025-0086","DOIUrl":"10.1515/dmpt-2025-0086","url":null,"abstract":"","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"197-198"},"PeriodicalIF":0.0,"publicationDate":"2025-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145762308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetic insights into MTHFR and SLC19A1 variants in low-dose methotrexate therapy for rheumatologic diseases. 低剂量甲氨蝶呤治疗风湿病的MTHFR和SLC19A1变异的药理学见解
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-20 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0047
Goitybell Martínez Téllez, Beatriz Marcheco Teruel

The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase (MTHFR) and solute carrier family 19 member 1 (SLC19A1) genes involved in methotrexate pathways. Over the past decade, several functional polymorphisms affecting methylenetetrahydrofolate reductase activity have been studied in the context of low-dose methotrexate therapy. The most frequently investigated polymorphisms are rs1801133 (c.665C>T) and rs1801131 (c.1286A>C) in MTHFR gene and rs1051266 (c.80A>G) in SLC19A1 gene. Although the effects of these polymorphisms are remaining unclear, several studies have shown association with adverse effect while fewer studies have demonstrated association with remission or positive response to methotrexate. However, there is scarcity research in Latin American population assessing the influence of genetic variants in the pharmacokinetics and pharmacodynamics of methotrexate in the context of interethnic admixture. There is an urgent need of to expand these studies and to support the development of clinical pharmacogenomics guidelines.

遗传标记的识别将使准确的诊断和预测治疗结果是治疗风湿病和自身免疫性疾病的关键一步。低剂量甲氨蝶呤是治疗的主要药物。本文综述了甲氨蝶呤通路中亚甲基四氢叶酸还原酶(MTHFR)和溶质载体家族19成员1 (SLC19A1)基因候选单核苷酸多态性的研究进展。在过去的十年中,在低剂量甲氨蝶呤治疗的背景下,研究了几种影响亚甲基四氢叶酸还原酶活性的功能多态性。研究最多的多态性是MTHFR基因的rs1801133 (C . 665c >T)和rs1801131 (C . 1286a >C)和SLC19A1基因的rs1051266 (C . 80a >G)。虽然这些多态性的影响尚不清楚,但一些研究表明与不良反应有关,而较少的研究表明与甲氨蝶呤缓解或阳性反应有关。然而,在拉丁美洲人群中,在种族混合的背景下,缺乏评估遗传变异对甲氨蝶呤药代动力学和药效学影响的研究。迫切需要扩大这些研究并支持临床药物基因组学指南的制定。
{"title":"Pharmacogenetic insights into <i>MTHFR</i> and <i>SLC19A1</i> variants in low-dose methotrexate therapy for rheumatologic diseases.","authors":"Goitybell Martínez Téllez, Beatriz Marcheco Teruel","doi":"10.1515/dmpt-2025-0047","DOIUrl":"10.1515/dmpt-2025-0047","url":null,"abstract":"<p><p>The identification of genetic markers that will enable accurate diagnosis and prediction of the therapy outcome is a crucial step in managing rheumatologic and autoimmune diseases. Low-dose methotrexate is a mainstay therapeutic agent for treatment. The objective of this review is to summarize the data on candidate single nucleotide polymorphisms in methylenetetrahydrofolate reductase (<i>MTHFR</i>) and solute carrier family 19 member 1 (<i>SLC19A1</i>) genes involved in methotrexate pathways. Over the past decade, several functional polymorphisms affecting methylenetetrahydrofolate reductase activity have been studied in the context of low-dose methotrexate therapy. The most frequently investigated polymorphisms are rs1801133 (c.665C>T) and rs1801131 (c.1286A>C) in <i>MTHFR</i> gene and rs1051266 (c.80A>G) in <i>SLC19A1</i> gene. Although the effects of these polymorphisms are remaining unclear, several studies have shown association with adverse effect while fewer studies have demonstrated association with remission or positive response to methotrexate. However, there is scarcity research in Latin American population assessing the influence of genetic variants in the pharmacokinetics and pharmacodynamics of methotrexate in the context of interethnic admixture. There is an urgent need of to expand these studies and to support the development of clinical pharmacogenomics guidelines.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"217-221"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of antimicrobial and immunomodulatory activities of Eugenol isolated from Syzygium aromaticum in a rat model. 丁香酚在大鼠模型中的抗菌和免疫调节活性评价。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-20 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0035
Raghad Abdulsalam Khaleel, Zinah Essam Hameed, Omar Hussein Ahmed

Objectives: The increasing resistance of human infections to pharmaceutical treatments represents a critical global health challenge. Traditional herbs may complement modern antibacterial strategies. This study investigates the antimicrobial, antioxidant, and immunomodulatory properties of Eugenol extracted from Syzygium aromaticum.

Methods: The essential oil was achieved through hydro distillation and analyzed using HPLC. Antioxidant capabilities were assessed using the DPPH radical scavenging assay and reducing power. MTT assays revealed the viability percentages of A549 and MRC5 cell lines after 48 h of exposure to methanolic extract and valerianic acid. Minimum inhibitory concentration (MIC) and broth microdilution methods were utilized to test antibiotic activity against Staphylococcus aureus, Escherichia coli, and Candida albicans. Finally, the essential oil (average concentration 13.1 % ± 0.23, with major components Eugenol, β-caryophyllene, and Eugenol Acetate) was orally administered to rats for 14 days. In vivo safety and immunomodulatory effects were assessed through histopathological, hematological, and hepatic enzyme analyses, as well as cytokine profiling.

Results: The essential oil, rich in Eugenol, β-caryophyllene, and Eugenol acetate, demonstrated strong antioxidant activity. It exhibited significant antimicrobial effects at concentrations≥5 mg/mL, with inhibition zones comparable to standard antibiotics. Cytotoxicity remained low, and in vivo analysis revealed no adverse effects. The extract also increased IFN-γ and IL-4 levels, indicating immunomodulatory potential.

Conclusions: The study indicated an immunomodulatory impact by increasing IFN-γ and IL-4 levels, with no negative effects on hepatic enzymes, hematological parameters, or histopathology. In summary, this research demonstrates that Eugenol, even at low concentrations, exhibits promising antioxidant and antimicrobial activities against common pathogens.

目标:人类感染对药物治疗的耐药性日益增强,是一项重大的全球卫生挑战。传统草药可以补充现代抗菌策略。本文研究了从香合木香中提取的丁香酚的抗菌、抗氧化和免疫调节特性。方法:采用水蒸气蒸馏法提取挥发油,HPLC法对挥发油进行分析。通过DPPH自由基清除试验和还原能力评估抗氧化能力。MTT试验显示A549和MRC5细胞系暴露于甲醇提取物和缬草酸48 h后的存活率。采用最低抑菌浓度法(MIC)和肉汤微量稀释法检测对金黄色葡萄球菌、大肠杆菌和白色念珠菌的抗菌活性。最后,以丁香酚、β-石竹烯、醋酸丁香酚为主要成分,以平均浓度13.1 %±0.23的浓度给药14 d。通过组织病理学、血液学和肝酶分析以及细胞因子分析来评估体内安全性和免疫调节作用。结果:丁香酚精油富含丁香酚、β-石竹烯和丁香酚醋酸酯,具有较强的抗氧化活性。当浓度≥5 mg/mL时,其抑菌效果显著,抑菌带与标准抗生素相当。细胞毒性仍然很低,体内分析显示没有不良反应。提取物还增加了IFN-γ和IL-4水平,表明免疫调节潜力。结论:该研究表明,增加IFN-γ和IL-4水平具有免疫调节作用,对肝酶、血液学参数或组织病理学无负面影响。总之,本研究表明,丁香酚即使在低浓度下,对常见病原体也具有良好的抗氧化和抗菌活性。
{"title":"Evaluation of antimicrobial and immunomodulatory activities of Eugenol isolated from Syzygium aromaticum in a rat model.","authors":"Raghad Abdulsalam Khaleel, Zinah Essam Hameed, Omar Hussein Ahmed","doi":"10.1515/dmpt-2025-0035","DOIUrl":"10.1515/dmpt-2025-0035","url":null,"abstract":"<p><strong>Objectives: </strong>The increasing resistance of human infections to pharmaceutical treatments represents a critical global health challenge. Traditional herbs may complement modern antibacterial strategies. This study investigates the antimicrobial, antioxidant, and immunomodulatory properties of Eugenol extracted from <i>Syzygium aromaticum</i>.</p><p><strong>Methods: </strong>The essential oil was achieved through hydro distillation and analyzed using HPLC. Antioxidant capabilities were assessed using the DPPH radical scavenging assay and reducing power. MTT assays revealed the viability percentages of A549 and MRC5 cell lines after 48 h of exposure to methanolic extract and valerianic acid. Minimum inhibitory concentration (MIC) and broth microdilution methods were utilized to test antibiotic activity against <i>Staphylococcus aureus</i>, <i>Escherichia coli</i>, and <i>Candida albicans</i>. Finally, the essential oil (average concentration 13.1 % ± 0.23, with major components Eugenol, β-caryophyllene, and Eugenol Acetate) was orally administered to rats for 14 days. <i>In vivo</i> safety and immunomodulatory effects were assessed through histopathological, hematological, and hepatic enzyme analyses, as well as cytokine profiling.</p><p><strong>Results: </strong>The essential oil, rich in Eugenol, β-caryophyllene, and Eugenol acetate, demonstrated strong antioxidant activity. It exhibited significant antimicrobial effects at concentrations≥5 mg/mL, with inhibition zones comparable to standard antibiotics. Cytotoxicity remained low, and <i>in vivo</i> analysis revealed no adverse effects. The extract also increased IFN-γ and IL-4 levels, indicating immunomodulatory potential.</p><p><strong>Conclusions: </strong>The study indicated an immunomodulatory impact by increasing IFN-γ and IL-4 levels, with no negative effects on hepatic enzymes, hematological parameters, or histopathology. In summary, this research demonstrates that Eugenol, even at low concentrations, exhibits promising antioxidant and antimicrobial activities against common pathogens.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"249-261"},"PeriodicalIF":0.0,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145556408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing the attitude to pharmacogenomics testing among pharmacists in Iraq. 评价伊拉克药师对药物基因组学检测的态度。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-19 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0065
Yazun Bashir Jarrar, Dina Abu Hashem, Mariam Homsi, Abdulqader Fadhil Abed, Yasmeen Ibrahim

Objectives: Pharmacogenomics (PGx) testing optimizes drug efficacy and minimizes adverse effects, yet its implementation in Iraq remains limited. This study assessed Iraqi pharmacists' attitudes toward PGx testing to identify gaps in education and clinical readiness.

Methods: A cross-sectional survey of 99 Iraqi pharmacists was conducted (June-August 2020). The 20-item questionnaire evaluated demographics, PGx education exposure, attitudes, and self-reported competence using a three-point Likert scale. Data were analyzed descriptively via SPSS.

Results: Most participants were young (83 % aged 21-30), held bachelor's degrees (87.88 %), and supported PGx integration into curricula (80.81 %). While 95 % believed pharmacists should possess PGx knowledge, self-reported competency was low (35-54 %).

Conclusions: Despite strong support for PGx, limited educational exposure and low confidence in applying PGx testing highlight the need for curriculum enhancements and targeted training programs in Iraq. Iraqi pharmacists recognize PGx's clinical value but require further education to bridge competence gaps. Policymakers should prioritize PGx training to facilitate implementation.

目的:药物基因组学(PGx)检测可优化药物疗效并最大限度地减少不良反应,但其在伊拉克的实施仍然有限。本研究评估了伊拉克药剂师对PGx测试的态度,以确定教育和临床准备方面的差距。方法:对99名伊拉克药师进行横断面调查(2020年6月- 8月)。20项问卷评估人口统计,PGx教育曝光,态度和自我报告能力使用三点李克特量表。数据通过SPSS进行描述性分析。结果:大多数参与者是年轻人(83% %,年龄在21-30岁之间),拥有学士学位(87.88 %),支持PGx融入课程(80.81 %)。95% %认为药师应具备PGx知识,但自述能力较低(35-54 %)。结论:尽管对PGx的大力支持,但有限的教育曝光和对应用PGx测试的低信心突出了伊拉克课程改进和有针对性的培训计划的必要性。伊拉克药剂师认识到PGx的临床价值,但需要进一步的教育,以弥合能力差距。决策者应优先考虑PGx培训,以促进实施。
{"title":"Assessing the attitude to pharmacogenomics testing among pharmacists in Iraq.","authors":"Yazun Bashir Jarrar, Dina Abu Hashem, Mariam Homsi, Abdulqader Fadhil Abed, Yasmeen Ibrahim","doi":"10.1515/dmpt-2025-0065","DOIUrl":"10.1515/dmpt-2025-0065","url":null,"abstract":"<p><strong>Objectives: </strong>Pharmacogenomics (PGx) testing optimizes drug efficacy and minimizes adverse effects, yet its implementation in Iraq remains limited. This study assessed Iraqi pharmacists' attitudes toward PGx testing to identify gaps in education and clinical readiness.</p><p><strong>Methods: </strong>A cross-sectional survey of 99 Iraqi pharmacists was conducted (June-August 2020). The 20-item questionnaire evaluated demographics, PGx education exposure, attitudes, and self-reported competence using a three-point Likert scale. Data were analyzed descriptively via SPSS.</p><p><strong>Results: </strong>Most participants were young (83 % aged 21-30), held bachelor's degrees (87.88 %), and supported PGx integration into curricula (80.81 %). While 95 % believed pharmacists should possess PGx knowledge, self-reported competency was low (35-54 %).</p><p><strong>Conclusions: </strong>Despite strong support for PGx, limited educational exposure and low confidence in applying PGx testing highlight the need for curriculum enhancements and targeted training programs in Iraq. Iraqi pharmacists recognize PGx's clinical value but require further education to bridge competence gaps. Policymakers should prioritize PGx training to facilitate implementation.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"243-248"},"PeriodicalIF":0.0,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145548725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neural network modelling of experimental diabetes to study new antidiabetic drugs. 实验性糖尿病的神经网络建模研究新型降糖药。
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-18 eCollection Date: 2025-12-01 DOI: 10.1515/dmpt-2025-0049
Zhansulu Nurgaliyeva, Ayazhan Dauletkaliyeva, Serzhan Dauletkaliyev, Dana Tolegen, Rauza Romanova

Objectives: Diabetes mellitus is a complex metabolic disease characterised by chronic hyperglycaemia, which triggers a cascade of pathological changes in the body. Contemporary methods for developing antidiabetic drugs are often lengthy, expensive, and not always effective. The use of neural networks for modelling diabetes opens up new possibilities for accelerating research and increasing the accuracy of predicting the effectiveness of novel therapeutic strategies. The aim of this study was to develop and validate a neural network for studying experimental diabetes and assessing the efficacy of new antidiabetic drugs, as well as to explore the potential of combined therapeutic strategies.

Methods: The empirical investigation was conducted using laboratory models of diabetes induced in rats with streptozotocin. Three groups were formed: a control group, a diabetic group without treatment, and a diabetic group treated with experimental drugs.

Results: A neural network, based on multilayer perceptrons and recurrent architectures, was trained to predict changes in glucose levels, oxidative stress markers, and the condition of pancreatic tissues. The developed model demonstrated high predictive accuracy of metabolic changes, with an average accuracy of 92.3 %. As a result of treatment with experimental drugs, blood glucose levels in rats decreased by 25-30 % over 28 days, accompanied by a 26 % reduction in oxidative stress markers and partial restoration of pancreatic β-cell function in 30 % of cases. Histological analysis confirmed reduced fibrosis and improved tissue condition in the treatment group. The model also identified that combined therapeutic strategies - for example, the combination of antioxidants with gluconeogenesis inhibitors - had a synergistic effect, lowering glucose levels by up to 40 %.

Conclusions: The study confirmed the effectiveness of the developed neural network for analysing therapeutic strategies and predicting metabolic changes in diabetes models. The proposed neural network represents a promising tool for investigating new antidiabetic drugs, including efficacy assessment within personalised medicine. Its application may accelerate preclinical research, optimise therapeutic approaches, and contribute to reducing drug development costs.

目的:糖尿病是一种以慢性高血糖为特征的复杂代谢性疾病,可引发体内一系列病理变化。目前研发抗糖尿病药物的方法往往耗时长、费用高,而且并不总是有效。利用神经网络对糖尿病进行建模,为加速研究和提高预测新治疗策略有效性的准确性开辟了新的可能性。本研究的目的是开发和验证神经网络用于研究实验性糖尿病和评估新的降糖药物的疗效,并探索联合治疗策略的潜力。方法:采用链脲佐菌素诱导大鼠糖尿病的实验室模型进行实证研究。实验分为三组:对照组、未经治疗的糖尿病组和使用实验药物治疗的糖尿病组。结果:一个基于多层感知器和循环架构的神经网络被训练来预测葡萄糖水平、氧化应激标志物和胰腺组织状况的变化。该模型对代谢变化的预测准确率较高,平均准确率为92.3 %。实验药物治疗的结果是,在28天内,大鼠的血糖水平下降了25- 30% %,同时在30% %的病例中,氧化应激标志物降低了26 %,胰腺β细胞功能部分恢复。组织学分析证实治疗组纤维化减少,组织状况改善。该模型还发现,联合治疗策略——例如,抗氧化剂与糖异生抑制剂的结合——具有协同效应,可将血糖水平降低高达40% %。结论:该研究证实了开发的神经网络在分析治疗策略和预测糖尿病模型代谢变化方面的有效性。提出的神经网络代表了一种有前途的工具,用于研究新的抗糖尿病药物,包括个体化药物的疗效评估。它的应用可以加速临床前研究,优化治疗方法,并有助于降低药物开发成本。
{"title":"Neural network modelling of experimental diabetes to study new antidiabetic drugs.","authors":"Zhansulu Nurgaliyeva, Ayazhan Dauletkaliyeva, Serzhan Dauletkaliyev, Dana Tolegen, Rauza Romanova","doi":"10.1515/dmpt-2025-0049","DOIUrl":"10.1515/dmpt-2025-0049","url":null,"abstract":"<p><strong>Objectives: </strong>Diabetes mellitus is a complex metabolic disease characterised by chronic hyperglycaemia, which triggers a cascade of pathological changes in the body. Contemporary methods for developing antidiabetic drugs are often lengthy, expensive, and not always effective. The use of neural networks for modelling diabetes opens up new possibilities for accelerating research and increasing the accuracy of predicting the effectiveness of novel therapeutic strategies. The aim of this study was to develop and validate a neural network for studying experimental diabetes and assessing the efficacy of new antidiabetic drugs, as well as to explore the potential of combined therapeutic strategies.</p><p><strong>Methods: </strong>The empirical investigation was conducted using laboratory models of diabetes induced in rats with streptozotocin. Three groups were formed: a control group, a diabetic group without treatment, and a diabetic group treated with experimental drugs.</p><p><strong>Results: </strong>A neural network, based on multilayer perceptrons and recurrent architectures, was trained to predict changes in glucose levels, oxidative stress markers, and the condition of pancreatic tissues. The developed model demonstrated high predictive accuracy of metabolic changes, with an average accuracy of 92.3 %. As a result of treatment with experimental drugs, blood glucose levels in rats decreased by 25-30 % over 28 days, accompanied by a 26 % reduction in oxidative stress markers and partial restoration of pancreatic β-cell function in 30 % of cases. Histological analysis confirmed reduced fibrosis and improved tissue condition in the treatment group. The model also identified that combined therapeutic strategies - for example, the combination of antioxidants with gluconeogenesis inhibitors - had a synergistic effect, lowering glucose levels by up to 40 %.</p><p><strong>Conclusions: </strong>The study confirmed the effectiveness of the developed neural network for analysing therapeutic strategies and predicting metabolic changes in diabetes models. The proposed neural network represents a promising tool for investigating new antidiabetic drugs, including efficacy assessment within personalised medicine. Its application may accelerate preclinical research, optimise therapeutic approaches, and contribute to reducing drug development costs.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":"231-241"},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry. c.557A >g变异与非洲-拉丁美洲血统人群DPYD药物遗传学实施的相关性
Q2 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2025-11-18 DOI: 10.1515/dmpt-2025-0070
Carla González de la Cruz, Fernanda Rodrigues-Soares, Mariela Guevara, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena

Fluoropyrimidines are chemotherapy treatments widely used in chemotherapeutic regimens for different types of cancer. Adverse effects produced by dihydropyrimidine dehydrogenase (DPD) enzyme deficiency due to single nucleotide variants (SNVs) in the limiting enzyme of fluoropyrimidine catabolism occur with a high frequency in the world population; however, clinical recommendation guidelines focus mainly on variants of DPD gene (DPYD), which are highly prevalent in European populations. The aim of this review is to identify clinically relevant DPYD variants considering ethnic origin in order to develop population-specific genotyping panels for Afro-Latin Americans. Current recommendations from clinical guidelines and scientific literature in populations of African origin, including Dominican, have been reviewed. Based on the high reported frequency, the inclusion of the c.557A>G variant (which leads to a decrease in DPD enzyme activity) in populations of Afro-Latin American ancestry is proposed.

氟嘧啶是一种广泛应用于不同类型癌症化疗方案的化疗药物。二氢嘧啶脱氢酶(DPD)酶缺乏症由于氟嘧啶分解代谢限制酶的单核苷酸变异(SNVs)而产生的不良反应在世界人群中发生的频率很高;然而,临床推荐指南主要关注DPD基因变异(DPYD),这在欧洲人群中非常普遍。本综述的目的是确定考虑种族起源的临床相关DPYD变异,以便为非裔拉丁美洲人开发人群特异性基因分型面板。目前对包括多米尼加在内的非洲裔人群的临床指南和科学文献的建议进行了审查。基于高频率的报道,c.557A >g变异(导致DPD酶活性降低)在非洲-拉丁美洲祖先人群中被包含。
{"title":"Relevance of the c.557A>G variant for the implementation of <i>DPYD</i> pharmacogenetics in populations with Afro-Latin American ancestry.","authors":"Carla González de la Cruz, Fernanda Rodrigues-Soares, Mariela Guevara, Ernesto Rodríguez, Caíque Manóchio, Eva Peñas-Lledó, Pedro Dorado, Adrián LLerena","doi":"10.1515/dmpt-2025-0070","DOIUrl":"https://doi.org/10.1515/dmpt-2025-0070","url":null,"abstract":"<p><p>Fluoropyrimidines are chemotherapy treatments widely used in chemotherapeutic regimens for different types of cancer. Adverse effects produced by dihydropyrimidine dehydrogenase (DPD) enzyme deficiency due to single nucleotide variants (SNVs) in the limiting enzyme of fluoropyrimidine catabolism occur with a high frequency in the world population; however, clinical recommendation guidelines focus mainly on variants of DPD gene (<i>DPYD</i>), which are highly prevalent in European populations. The aim of this review is to identify clinically relevant <i>DPYD</i> variants considering ethnic origin in order to develop population-specific genotyping panels for Afro-Latin Americans. Current recommendations from clinical guidelines and scientific literature in populations of African origin, including Dominican, have been reviewed. Based on the high reported frequency, the inclusion of the c.557A>G variant (which leads to a decrease in DPD enzyme activity) in populations of Afro-Latin American ancestry is proposed.</p>","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145539703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Drug metabolism and personalized therapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1